908 Devices Appoints Dr. Brandi Vann to Board, Jeff George Steps Down

908 Devices Inc. has appointed Dr. Brandi Vann to its Board of Directors. Dr. Vann previously held various leadership positions at the U.S. Department of Defense, overseeing nuclear, chemical, and biological defense programs. Jeff George, a veteran biopharma leader, has stepped down from the Board due to the company's strategic refocus on public health, safety, and defense technology. The changes are effective immediately.

908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, has appointed Dr. Brandi Vann to its Board of Directors. Dr. Vann brings extensive experience in nuclear, chemical, and biological defense programs from her tenure at the U.S. Department of Defense (DoD). Concurrently, veteran biopharma leader Jeff George has stepped down from the Board due to the company's strategic shift towards public health, safety, and defense technology. These changes are effective immediately.

Dr. Vann's appointment marks a significant addition to the Board, given her extensive background in CBRN (Chemical, Biological, Radiological, and Nuclear) detection and defense. She previously held leadership positions such as Performing the Duties of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs and Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense at the DoD. Her roles included advising on nuclear weapons, nuclear energy, chemical and biological defense programs, chemical demilitarization, and treaty management. From September 2019 through January 2022, she served as Deputy Assistant Secretary of Defense for Chemical and Biological Defense.

At the Defense Threat Reduction Agency (DTRA), Dr. Vann held various positions, including Chief of the Advanced and Emerging Threats Division from 2017 to 2019, where she led efforts for the characterization of advanced and emerging chemical and biological threats. Her experience and expertise in nuclear, chemical, and biological defense should be instrumental in shaping and executing 908 Devices' strategy for commercializing advanced chemical detection devices.

Jeff George, who has been a significant contributor to the Board, including as chair of the compensation committee, is stepping down to focus on other strategic priorities. His contributions have been invaluable in shaping the company's bioprocessing strategy and divestiture.

Kevin J. Knopp, CEO and Co-founder of 908 Devices, expressed his enthusiasm for Dr. Vann's appointment, stating, "Her many years of leadership in CBRN detection enhance the strategic counsel of our board as we navigate opportunities in national security and global preparedness." Dr. Vann herself is honored to join the Board and support the company's mission to equip military personnel and first responders with field-ready devices for rapid chemical threat identification.

908 Devices continues to revolutionize chemical analysis with its simple handheld devices, addressing vital health, safety, and defense applications. The company's innovative products combine complementary analytical technologies, software automation, and machine learning to tackle issues such as the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats.

References:
[1] https://www.morningstar.com/news/business-wire/20250804446788/908-devices-appoints-dr-brandi-vann-former-us-principal-deputy-assistant-secretary-for-nuclear-chemical-and-biological-defense-to-its-board-of-directors
[2] https://www.nasdaq.com/press-release/908-devices-appoints-dr-brandi-vann-former-us-principal-deputy-assistant-secretary